Physician profile
Taylor Ripper
NPI 1275091530
$4,375.14
in general payments reported to CMS, 2019-2025
26 companies · $957 in 2025
The $957 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $457 · 2022: $1,033 · 2023: $1,024 · 2024: $904 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,884.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $778.58 | 2022-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $771.61 | 2021-2025 | Relistor |
| Abbvie INC. | $628.86 | 2021-2025 | |
| Pfizer INC. | $380.57 | 2023-2025 | |
| Abbott Laboratories | $339.39 | 2023-2025 | Proclaim, Eterna |
| Redhill Biopharma INC. | $215.12 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $198.06 | 2023-2025 | Horizant, Horizant |
| Idorsia Pharmaceuticals US INC | $186.64 | 2022-2024 | Quviviq |
| Lilly USA, LLC | $151.03 | 2022-2024 | Emgality, Reyvow |
| Almatica Pharma LLC | $99.16 | 2022-2023 | Gralise |
| Allergan, INC. | $76.51 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $70.91 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $57.11 | 2023 | Seglentis |
| Biohaven Pharmaceutical Holding Company LTD. | $53.13 | 2022 | |
| Horizon Therapeutics Plc | $52.14 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.91 | 2021-2022 | |
| Ibsa Pharma INC. | $44.20 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $43.09 | 2025 | |
| Eisai INC. | $38.27 | 2022 | |
| Axsome Therapeutics, INC. | $28.76 | 2025 | Symbravo |
| Merz Pharmaceuticals, LLC | $24.28 | 2025 | Xeomin |
| Tonix Medicines, INC. | $23.19 | 2025 | Tonmya |
| Nevro Corp. | $18.92 | 2023 | Senza |
| Impel Pharmaceuticals LLC | $17.18 | 2025 | Trudhesa |
| Boston Scientific Corporation | $16.61 | 2024 | |
| Fidia Pharma USA INC. | $14.91 | 2023 | Triluron, Hymovis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Ripper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.